SKINVISIBLE, INC.
SKVI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SKVI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SKVI
Skinvisible, Inc. is a development-stage biopharmaceutical company focused on its topical and transdermal drug delivery platform, with no current product revenue and a history of operating losses.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Market Cap
$973K
Cash Runway
—
Lead Asset
procort (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for SKINVISIBLE, INC..
Skinvisible, Inc. is a development-stage biopharmaceutical company focused on its topical and transdermal drug delivery platform, with no current product revenue and a history of operating losses.
- Skinvisible has incurred cumulative net losses of $41,532,893 since inception [sec_mda · as of 2026-08-13].
- As of June 30, 2026, the company reported $0.0M in cash and equivalents, $0.0M in total revenue, and a net loss of $0.3M for the quarter [sec].
- The company is actively pursuing strategic partnerships to commercialize transdermal obesity therapies and other applications of its delivery platform [sec_mda · as of 2026-08-13].
- Revenue for the three and six months ended June 30, 2026 was $5,000, unchanged from the same periods in 2025 [sec_mda · as of 2026-08-13].
- The company's financial statements include a going concern qualification, indicating substantial doubt about its ability to continue operations [sec_mda · as of 2026-08-13].
What works
- The company is actively pursuing strategic partnerships with pharmaceutical and/or biotech companies to commercialize its transdermal delivery platform for obesity therapies and other disease domains [sec_mda · as of 2026-08-13].
- Skinvisible has existing license agreements with Quoin and Ovation, from which it hopes to generate more revenue in 2026 [sec_mda · as of 2026-05-13].
What to weigh
- The company has incurred cumulative net losses of $41,532,893 since inception and requires capital for its contemplated operational and marketing activities [sec_mda · as of 2026-08-13].
- As of June 30, 2026, the company had $0.0M in cash and equivalents and negative shareholders' equity of $9.2M, indicating severe liquidity constraints [sec].
- The company's ability to generate necessary funds through licensing or additional capital raises is unknown, raising substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-08-13].
- Revenue has been minimal and flat at $5,000 per quarter, with no product sales generating meaningful income [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
The company has a history of operating losses and a going concern qualification.
“The Company has incurred cumulative net losses of $41,532,893 since its inception and requires capital for its contemplated operational and marketing activities to take place.”
SEC MD&A · August 13, 2026
The company is pursuing partnerships for transdermal obesity therapies.
“We are actively pursuing strategic partnerships with pharmaceutical and/or biotech companies to facilitate the introduction of the first transdermal obesity therapies to market and to explore the application of its delivery platform across diverse disease domains.”
SEC MD&A · August 13, 2026
Revenue is minimal and unchanged year-over-year.
“Our revenue, which we combine from product sales, royalties on patent licenses and license fees (product development fees), was $5,000 for the three months ended June 30, 2026 as compared with $5,000 for the same period ended June 30, 2025.”
SEC MD&A · August 13, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue operations due to cumulative losses and lack of capital [sec_mda · as of 2026-08-13].
- No cash or revenue — As of June 30, 2026, cash and equivalents were $0.0M and revenue was $0.0M [sec].
- Dependence on partnerships — Future success relies on securing strategic partnerships, which are uncertain [sec_mda · as of 2026-08-13].
- Minimal and flat revenue — Quarterly revenue has been only $5,000 for multiple periods, with no growth [sec_mda · as of 2026-08-13].
What to watch
- Ability to secure additional financing or strategic partnerships to fund operations [sec_mda · as of 2026-08-13].
- Progress on licensing deals with Quoin and Ovation and potential revenue from those agreements [sec_mda · as of 2026-05-13].
- Any updates on the development or commercialization of transdermal obesity therapies [sec_mda · as of 2026-08-13].
- Future financial filings for signs of improved liquidity or revenue generation [sec_mda · as of 2026-08-13].
Sources: SEC MD&A · Generated August 14, 2026 · How we verify sources →
Run SKINVISIBLE, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SKINVISIBLE, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Profitable (positive operating cash flow)
OCF $2K · Net income -$256K
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for SKINVISIBLE, INC.?
Skinvisible, Inc. is a development-stage biopharmaceutical company focused on its topical and transdermal drug delivery platform, with no current product revenue and a history of operating losses.
What is SKINVISIBLE, INC.'s lead drug candidate?
SKINVISIBLE, INC.'s most advanced tracked candidate is procort (Approved) for Hemorrhoids.
Who is the CEO of SKINVISIBLE, INC.?
Mr. Terry H. Howlett is the chief executive officer of SKINVISIBLE, INC. (SKVI).
Where is SKINVISIBLE, INC. headquartered?
SKINVISIBLE, INC. (SKVI) is headquartered in Las Vegas, NV, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.